Total Payments
$240,782
2024 Payments
$14,688
Companies
22
Transactions
147
Medicare Patients
656
Medicare Billing
$105,492
Payment Breakdown by Category
Consulting$127,348 (52.9%)
Research$52,430 (21.8%)
Other$35,480 (14.7%)
Travel$20,708 (8.6%)
Food & Beverage$4,691 (1.9%)
Education$125.01 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $127,348 | 39 | 52.9% |
| Unspecified | $52,430 | 15 | 21.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,980 | 4 | 13.7% |
| Travel and Lodging | $20,708 | 32 | 8.6% |
| Food and Beverage | $4,691 | 49 | 1.9% |
| Honoraria | $2,500 | 5 | 1.0% |
| Education | $125.01 | 3 | 0.1% |
Payments by Type
General
$188,352
132 transactions
Research
$52,430
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $112,143 | 47 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $25,125 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $24,957 | 26 | $0 (2023) |
| Hexal AG | $19,952 | 12 | $0 (2023) |
| PFIZER INC. | $12,923 | 3 | $0 (2024) |
| AstraZeneca UK Limited | $10,850 | 2 | $0 (2020) |
| BeiGene, Ltd. | $10,725 | 3 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $5,800 | 6 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $4,612 | 8 | $0 (2023) |
| Gilead Sciences, Inc. | $4,203 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,688 | 8 | Regeneron Pharmaceuticals, Inc. ($10,250) |
| 2023 | $27,790 | 18 | PFIZER INC. ($8,673) |
| 2022 | $29,624 | 23 | Regeneron Pharmaceuticals, Inc. ($8,750) |
| 2021 | $12,272 | 8 | AstraZeneca Pharmaceuticals LP ($5,138) |
| 2020 | $28,080 | 10 | Amgen Inc. ($16,655) |
| 2019 | $39,992 | 11 | Amgen Inc. ($30,790) |
| 2018 | $36,767 | 29 | Amgen Inc. ($27,930) |
| 2017 | $51,568 | 40 | Amgen Inc. ($29,555) |
All Payment Transactions
147 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $139.63 | General |
| 12/09/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 08/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,250.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 08/22/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: BioOncology | ||||||
| 06/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,750.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 01/05/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,250.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 12/19/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,490.00 | General |
| 12/07/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $50.39 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $61.43 | General |
| Category: ONC | ||||||
| 12/06/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $40.82 | General |
| Category: Oncology | ||||||
| 12/05/2023 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 10/13/2023 | PFIZER INC. | IBRANCE (Drug) | — | Cash or cash equivalent | $8,673.00 | Research |
| Study: CTDNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ER HER2 EARLY STAGE BREAST CANCER DAREWI251141 • Category: ONCOLOGY | ||||||
| 10/04/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: Oncology | ||||||
| 06/30/2023 | G1 Therapeutics, Inc. | COSELA (Drug) | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) • Category: Oncology | ||||||
| 06/27/2023 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: Oncology | ||||||
| 06/20/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,375.00 | Research |
| Study: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 06/04/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $37.29 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $58.44 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $41.83 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $649.00 | General |
| Category: Oncology | ||||||
| 02/21/2023 | Hexal AG | — | Consulting Fee | Cash or cash equivalent | $3,713.00 | General |
| 02/08/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| Category: Oncology | ||||||
| 01/25/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $25,125 | 7 |
| CTDNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ER HER2 EARLY STAGE BREAST CANCER DAREWI251141 | PFIZER INC. | $8,673 | 1 |
| This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR and Rad3 related protein kinase and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 in second or third line setting in patients with Triple negative breast cancer prospectively stratified by presence absence of qualifying tumour mutation in genes involved in the homologous recombination repair pathway | AstraZeneca UK Limited | $8,575 | 1 |
| Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States | Amgen Inc. | $5,650 | 1 |
| A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) | G1 Therapeutics, Inc. | $2,538 | 2 |
| A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) | G1 Therapeutics, Inc. | $1,050 | 1 |
| Risk Factors Associated With Skeletal-Related Events Following Denosumab Cessation Among Patients W | Amgen Inc. | $608.85 | 1 |
| Identify SRE Risk Factors following XGEVA Discontinuation in Pts with Bone Mets from Solid Tumors | Amgen Inc. | $210.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 169 | 289 | $89,975 | $28,884 |
| 2022 | 10 | 247 | 390 | $110,820 | $36,261 |
| 2021 | 5 | 140 | 265 | $70,535 | $26,391 |
| 2020 | 3 | 100 | 178 | $40,220 | $13,956 |
Total Patients
656
Total Services
1,122
Medicare Billing
$105,492
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 45 | 103 | $37,080 | $11,549 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 67 | 96 | $23,565 | $7,281 | 30.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $9,320 | $2,982 | 32.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 25 | $7,380 | $2,776 | 37.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 35 | $6,960 | $2,585 | 37.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $5,670 | $1,712 | 30.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 95 | $34,200 | $10,490 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 74 | 111 | $27,195 | $8,029 | 29.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 38 | $10,260 | $3,654 | 35.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 52 | $10,140 | $3,492 | 34.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $6,695 | $2,438 | 36.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $6,380 | $2,374 | 37.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $6,230 | $2,296 | 36.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 14 | 14 | $3,990 | $1,371 | 34.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 17 | 18 | $3,330 | $1,225 | 36.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 16 | 24 | $2,400 | $893.08 | 37.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 93 | $28,665 | $11,050 | 38.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 67 | 109 | $23,950 | $8,590 | 35.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $6,520 | $2,587 | 39.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 24 | $6,300 | $2,333 | 37.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 27 | $5,100 | $1,830 | 35.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 93 | $24,600 | $8,405 | 34.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 54 | 69 | $12,780 | $4,470 | 35.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 16 | $2,840 | $1,082 | 38.1% |
About Dr. Alison Stopeck, MD
Dr. Alison Stopeck, MD is a Hematology & Oncology healthcare provider based in Tucson, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144392291.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alison Stopeck, MD has received a total of $240,782 in payments from pharmaceutical and medical device companies, with $14,688 received in 2024. These payments were reported across 147 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($127,348).
As a Medicare-enrolled provider, Stopeck has provided services to 656 Medicare beneficiaries, totaling 1,122 services with total Medicare billing of $105,492. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tucson, AZ
- Active Since 11/14/2006
- Last Updated 02/02/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1144392291
Products in Payments
- XGEVA (Biological) $104,590
- LIBTAYO (Biological) $25,125
- LYNPARZA (Drug) $9,435
- IBRANCE (Drug) $8,673
- BRUKINSA (Drug) $4,550
- KISQALI (Drug) $4,544
- COSELA (Drug) $3,588
- ENHERTU (Biological) $3,083
- Oral Paclitaxel (Drug) $2,522
- Orserdu (Drug) $2,517
- Nplate (Biological) $1,298
- JARDIANCE (Drug) $400.00
- Enhertu (Drug) $146.24
- Trodelvy (Drug) $61.43
- ENHERTU (Drug) $38.07
- Tecentriq (Biological) $30.00
- Zoladex (Drug) $21.95
- Kyprolis (Biological) $21.58
- KEYTRUDA (Biological) $18.09
- Nerlynx (Drug) $17.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tucson
Dr. Christopher Chen, Md, Mba, MD, MBA
Hematology & Oncology — Payments: $312,281
Hematology & Oncology $312,281
Dr. Rachna Shroff, Md, MD
Hematology & Oncology — Payments: $257,150
Hematology & Oncology $257,150
Michael Boxer, M.d, M.D
Hematology & Oncology — Payments: $86,711
Hematology & Oncology $86,711
Dr. Rachel Swart, M.d.,Ph.d, M.D.,PH.D
Hematology & Oncology — Payments: $69,563
Hematology & Oncology $69,563
Sudhir Manda, Md, MD
Hematology & Oncology — Payments: $50,979
Hematology & Oncology $50,979
Basel Shoua, M.d, M.D
Hematology & Oncology — Payments: $45,611
Hematology & Oncology $45,611